Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Four and a half LIM domain (FHL) proteins are members of the LIM protein superfamily. Several FHL proteins function as co-activators of CREM/CREB transcription factors and the androgen receptor.
FHL3
is highly expressed in skeletal muscle, but its function is unknown.
FHL3
localized to the nucleus in C2C12 myoblasts and, following integrin engagement, exited the nucleus and localized to actin stress fibers and focal adhesions. In mature skeletal muscle
FHL3
was found at the Z-line. Actin was identified as a potential
FHL3
binding partner in yeast two-hybrid screening of a skeletal muscle library.
FHL3
complexed with actin both in vitro and in vivo as shown by
glutathione S-transferase
pull-down assays and co-immunoprecipitation of recombinant and endogenous proteins.
FHL3
promoted cell spreading and when overexpressed in spread C2C12 cells disrupted actin stress fibers. Increased
FHL3
expression was detected in highly motile cells migrating into an artificial wound, compared with non-motile cells. The molecular mechanism by which
FHL3
induced actin stress fiber disassembly was demonstrated by low speed actin co-sedimentation assays and electron microscopy.
FHL3
inhibited alpha-actinin-mediated actin bundling. These studies reveal
FHL3
as a significant regulator of actin cytoskeletal dynamics in skeletal myoblasts.
...
PMID:FHL3 is an actin-binding protein that regulates alpha-actinin-mediated actin bundling: FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassembly. 1270 94
MyoD initiates muscle differentiation and promotes skeletal myogenesis by regulating temporal gene expression. MyoD-interacting proteins induce regulatory effects, and the identification of new MyoD-binding partners may provide mechanistic insights into the regulation of gene expression during myogenesis.
FHL3
is one of three members of the FHL protein family that are expressed in skeletal muscle, but its function in myogenesis is unknown. Overexpression of human
FHL3
in mouse C2C12 cells retarded myotube formation and decreased the expression of muscle-specific regulatory genes such as myogenin but not MyoD. By contrast, short interfering RNA (siRNA)-mediated FHL3 protein knockdown enhanced myoblast differentiation associated with increased myogenin, but not MyoD protein expression, early during differentiation. We demonstrate that
FHL3
is a MyoD-associated protein by direct binding assays, colocalisation in the nucleus of myoblasts and
GST
pull-down studies. Moreover, we determined that
FHL3
interacts with MyoD, functioning as its potent negative co-transcriptional regulator. Ectopic expression of
FHL3
in myoblasts impaired MyoD-mediated transcriptional activity and muscle gene expression. By contrast, siRNA-mediated
FHL3
knockdown enhanced MyoD transcriptional activity in a dose-dependent manner. These findings reveal that
FHL3
association with MyoD may contribute to the regulation of MyoD-dependent transcription of muscle genes and thereby myogenesis.
...
PMID:FHL3 binds MyoD and negatively regulates myotube formation. 1738 85